Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 1 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. WO 2026106858

    FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES

    BAYER HEALTHCARE LLC [US] · Granted May 21, 2026 · Expires May 16, 2046

    granted
  2. US 20260108463

    NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION

    BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Apr 23, 2026 · Expires Apr 18, 2046

    granted
  3. US 20260096994

    SOLID DISPERSIONS HAVING STABILIZED EMULSION PARTICLES

    BOEHRINGER INGELHEIM INT [DE] · Granted Apr 9, 2026 · Expires Apr 4, 2046

    granted
  4. WO 2026033885

    POLYTHÉRAPIE FAISANT INTERVENIR DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2

    ASTELLAS PHARMA INC [JP] · Granted Feb 12, 2026 · Expires Feb 7, 2046

    granted
  5. WO 2026024938

    MÉTHODES DE RÉDUCTION DE LA TRANSMISSION INTRA-UTÉRINE D'UNE INFECTION À SALMONELLA DUBLIN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Jan 29, 2026 · Expires Jan 24, 2046

    granted
  6. WO 2026015429

    BONBONS GOMMEUX À COMPRESSION DIRECTE

    BAYER HEALTHCARE LLC [US] · Granted Jan 15, 2026 · Expires Jan 10, 2046

    granted
  7. WO 2025260042

    CONSTRUCTIONS D'ARNI ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE CNR1

    AMGEN INC [US] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  8. WO 2025252204

    DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF

    BEIGENE SUZHOU CO LTD [CN] · Granted Dec 11, 2025 · Expires Dec 6, 2045

    granted
  9. WO 2025242583

    NOUVELLE FORMULATION COMPRENANT DE L'ÉLINZANÉTANT DANS UNE DISPERSION SOLIDE

    BAYER CONSUMER CARE AG [CH] · Granted Nov 27, 2025 · Expires Nov 22, 2045

    granted
  10. WO 2025233516

    MÉTHODE D'AUGMENTATION DU TEMPS JUSQU'À LA DEUXIÈME PROGRESSION ET DU TEMPS JUSQU'À LA PREMIÈRE CHIMIOTHÉRAPIE SUIVANTE

    ASTRAZENECA AB [SE] · Granted Nov 13, 2025 · Expires Nov 8, 2045

    granted
  11. US 12419920

    Bifidobacterium longum NCIMB 41676

    PrecisionBiotics Group Limited · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  12. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    The Regents of the University of California · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  13. US 12409188

    Modulators of HSD17B13 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  14. US 12410418

    Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

    Precision BioSciences, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  15. US 12410430

    Modulating apolipoprotein (A) expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  16. US 12404313

    GDNF fusion polypeptides and methods of use thereof

    Keros Therapeutics, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  17. US 12404297

    Salts and crystal forms of GABA-A positive allosteric modulator

    PRAXIS PRECISION MEDICINES, INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  18. US 12403192

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  19. US 12404497

    Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof

    Medicenna Therapeutics Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  20. US 12396988

    Methods of using muscarinic antagonists in the treatment of depression

    The Board of Regents of the University of Texas System · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  21. US 12390509

    Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof

    Larimar Therapeutics, Inc. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  22. US 12383516

    Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

    Amphastar Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  23. US 12383618

    Expression vector delivery system and use thereof for inducing an immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  24. US 12383566

    Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity

    Northwestern University · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted